If Mdm2 is blocking the p53-pathway in estrogen receptor positive breast cancer cells then the conventional chemotherapeutics that rely on the p53 tumor suppressor, a major cell death regulator [31], may not activate cell death effectively. Here, ESR1 is linked to breast cancer.